| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
|
|
|||||||||
|
|
Oncology-Clinical Diagnosis: Solid TumorsClinical Diagnosis-Solid Tumors Posters |
1 Dept. of Nuclear Medicine; 2 Dept. of Oncology, University Hospital Zuerich, Zuerich, Switzerland
1552
Objectives: To assess prospectively the diagnostic performance and therapeutic influence of a whole-body DOPA-PET/CT with integrated triple-phase contrast enhancement (cePET/CT) in patients with neuroendocrine tumors.
Methods: 34 patients (20 male, 14 female) with suspected or known neuroendocrine tumors underwent a DOPA-cePET/CT. Histopathology from biopsies, surgery as well as clinical follow up (mean time: 7 month) served as the standard of reference. Therapeutic influence of the cePET/CT examination was prospectively determined based on the therapeutic procedures induced by the findings of the DOPA-cePET/CT.
Results: In 16 patients no suspicious lesions were found, in 18 patients metastastic lesions were detected by the DOPA-cePET/CT. Overall, 133 metastases (mainly: 75 liver lesions, 24 lymph nodes, 16 bone metastases and 7pulmonary lesions, several singular lesions) were detected, 12 were DOPA-negative but were detected by the triple-phase CT-part of the ce-PET/CT. In one patient, 2 metastases were overlooked by ce-PET/CT (found by MRI during follow-up). In 5/18 (28%) patients, the so far unknown primary tumor was found in the small bowel or in the pancreas. In 7/18 (39%) patients, findings of the DOPA ce-PET/CT lead to subsequent significant therapeutic changes.
Conclusions: Whole-body DOPA-cePET/CT detected the vast majority of distant metastases and was able to visualize the so far not detectable primary tumors in several patients, leading to significant therapeutic influence. Thus, whole-body DOPA-cePET/CT might be a valuable tool for staging purposes in patients with selected neuroendocrine tumors.
| ||||||||||||||||||||||||||||||||||||||
